Burgio, Gaetan2022-11-292573-1599http://hdl.handle.net/1885/281378The use of Class II CRISPR* effector systems to edit the human genome for therapeutic purposes is potentially a game changer due to their versatility, simplicity of use, and relatively low cellular toxicity.application/pdfen-AU© 2018 The authors201810.1089/crispr.2018.29002.gbu2021-11-28